Guangzhou Kingmed Diagnostics Group Co., Ltd. Stock: price and insider trades · China
金域医学
No insider purchase over the last 90 days. The latest, by 郝必喜, was filed 15 Jul 2024.
Guangzhou Kingmed Diagnostics Group Co., Ltd.: what insiders have been doing
This page follows insider dealings at Guangzhou Kingmed Diagnostics Group Co., Ltd. as filed with SSE / SZSE (CSRC), a company from the Health Care sector. No insider at Guangzhou Kingmed Diagnostics Group Co., Ltd. has published a filing in the past twelve months. The most recent one dates from 15 July 2024.
Our records for Guangzhou Kingmed Diagnostics Group Co., Ltd. go back to 2021, with 2 purchases and 1 sale on the open market in total.
In the same sector, recent insider purchases at Dynavox Group AB and Vetoquinol SA also feature in our signals. These figures are compiled from regulatory filings published by SSE / SZSE (CSRC). They describe what insiders did and are not a recommendation.
Since the insiders bought
- -0.5%Entry CN¥29.24 · Close at T+365 CN¥29.10
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
- 17,500 shares33.2% of flowA股XSHGSSE:173000007843918880Canonical exit: 13 Oct 2024 (T+90)
- 35,000 shares66.8% of flowA股XSHGSSE:173000007833901730Canonical exit: 9 Oct 2024 (T+90)
- 5,000 shares100.0% of flowA股XSHGSSE:173000004478247600
3 of 3 declarations
About Guangzhou Kingmed Diagnostics Group Co., Ltd.
金域医学 is a company specializing in medical diagnostic services and laboratory testing in China. It provides innovative and high-quality health solutions for healthcare professionals.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
